Nuvation Bio Logs 216 Q4 IBTROZI Starts, Signs Eisai Deal and $529M Cash
Nuvation Bio started 216 patients on IBTROZI in Q4, totaling 432 new starts since its June launch and received a $25 million milestone from Nippon Kayaku for Japanese reimbursement. The company secured an exclusive Eisai licensing deal for taletrectinib across Europe and other territories and held $529.2 million in cash.
1. Robust IBTROZI Adoption
In Q4 2025, Nuvation Bio initiated IBTROZI treatment in 216 patients, bringing total new patient starts to 432 since the June launch. This adoption rate is approximately six times that of prior ROS1 TKI launches and generated a $25 million milestone payment from Nippon Kayaku for Japanese reimbursement.
2. Eisai Licensing Collaboration
On January 11, 2026, Nuvation Bio entered an exclusive licensing and collaboration agreement with Eisai Co., Ltd. to develop, register, and commercialize taletrectinib in Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand, and select Asia-Pacific countries.
3. Strong Financial Position
The company held $529.2 million in cash, cash equivalents, and marketable securities as of December 31, 2025. Net product revenue from U.S. IBTROZI sales reached $15.7 million in Q4 and $24.7 million for full-year 2025, while collaboration and license revenues totaled $26.2 million in the quarter and $38.2 million for the year.
4. Safusidenib Pipeline Advancement
Positive Phase 2 data for safusidenib in grade 2 IDH1-mutant glioma showed a 44% overall response rate and 88% progression-free rate at 24 months. The SIGMA study has advanced to a pivotal Phase 3 trial in high-risk and high-grade cohorts, including an exploratory grade 3 oligodendroglioma arm.